ActiTrexx GmbH prevent the development of GvHD at an early stage with the cellular therapy ATreg and thus to provide a curative therapy
ActiTrexx has raised €3.5M across 1 funding round from 1 investor, most recently a round in Mar 2021. Based in Mainz, Germany; founded 2019; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-03-02 | Other | €3.5M |
| LBBW VC |
| View deal → |
